CD274 and neoplasm: While therapy with anti-PDL1 mAb did not significantly inhibit tumor proliferation, treatment with the sMIC-targeting mAb B10G5 evidently reduced tumor proliferation as compared to control cIgG treatment (Fig. 2a).